The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder

Apr 4, 2025Journal of clinical psychopharmacology

Glucagon-Like Peptide-1 Receptor Agonists as a Possible Treatment for Alcohol Use Disorder: Current Findings and Future Prospects

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists may decrease heavy drinking days in certain groups, particularly those with concurrent obesity.

Animal studies show that activating GLP-1 receptors can significantly reduce alcohol intake and prevent relapse.
Initial clinical trials suggest that GLP-1 receptor agonists may be effective in decreasing alcohol consumption among individuals with obesity.
There are notable gaps in current research, including a need for longer studies and more diverse human trial participants.
Investigations into genetic factors affecting treatment outcomes for alcohol use disorder are also needed.

AI simplified

Alcohol use disorder (AUD) poses a substantial challenge to public health, marked by persistent alcohol consumption patterns that result in significant morbidity and mortality. The limited efficacy of current pharmacological treatments for AUD underscores the necessity for novel therapeutic approaches. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed to treat type 2 diabetes and obesity, have shown promise as potential AUD treatments due to their influence on brain reward pathways. This narrative review synthesizes existing preclinical and clinical evidence on the effects of GLP-1 receptor agonists on alcohol-related behaviors and consumption. Animal studies demonstrate that activating GLP-1 receptors can substantially reduce alcohol intake and inhibit relapse. Initial clinical trials indicate that these agents may decrease heavy drinking days in certain groups, particularly those with concurrent obesity. However, significant gaps remain in the research, including the need for extended studies, more diverse human trials, and investigations into genetic influences on treatment outcomes. This review emphasizes the potential of GLP-1 receptor agonists in AUD treatment and advocates for additional research to confirm their effectiveness and safety in clinical contexts, potentially leading to innovative strategies for managing AUD.

Full Text

Full text is available at the source.

View full text ↗

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief